Plasma Levels of Amino Acids Related to Urea Cycle and Risk of Type 2 Diabetes Mellitus in Chinese Adults

Yun-Feng Cao 1†, Jing Li 2†, Zhipeng Zhang 3†, Jinnan Liu 4, Xiao-Yu Sun 4, Xiao-Fei Feng 5, Hui-Huan Luo 5, Wen Yang 2, Sai-Nan Li 5, Xilin Yang 2,6*, Zhong-Ze Fang 5,6*

*Correspondence: Xilin Yang yxl@hotmail.com; yangxilin@tmu.edu.cn
†These authors have contributed equally to this work

Objective: This study aimed to test associations between type 2 diabetes mellitus (T2DM) and metabolites in urea cycle including arginine, citrulline and ornithine.

Methods: This study used a hospital-based cross-sectional study design. We retrieved medical notes of 401 in-patients with onset of T2DM within 2 years and 1,522 healthy subjects who attended annual physical examination. All cases were admitted to a tertiary care center in Jinzhou, China from May 2015 to August 2016. Binary logistic regression analyses were performed to obtain odds ratios (ORs) and 95% confidence intervals (CIs).

Results: Patients with T2DM had higher arginine, and lower ornithine than control subjects. Levels of citrulline were similar in two groups. Arginine was positively associated with T2DM (ORs: 1.20, 1.17–1.23) while ornithine was negatively associated with T2DM (OR: 0.89, 0.88–0.91). After adjustment for other amino acids and traditional risk factors, these associations were still significant and persistent for arginine and ornithine. The association between citrulline and T2DM was not significant. Their ratios of pairs of two amino acids were associated with increased risk of T2DM. After adjustment for other ratios of amino acids, effect size for T2DM remained significant. Further adjustment for traditional risk factors did not lead to large changes (ORs: 1.78, 1.20–2.65 for the ratio of arginine to ornithine; ORs: 1.59, 1.37–1.86 for the ratio of citrulline to ornithine, respectively) except the ratio of arginine to citrulline.

Conclusions: Plasma levels of amino acids related to urea cycle and their ratios of these amino-acids were associated with T2DM in Chinese adults.

Keywords: type 2 diabetes, amino acid, urea cycle, metabolism, Chinese

INTRODUCTION

Prevalence of diabetes has been continuing to soar in the world and the number of people with type 2 diabetes mellitus (T2DM) was estimated to hit 642 million by 2040 (1). T2DM is associated with serious complications (e.g., cardiovascular disease, kidney failure, and blindness) (2, 3) and contributes to an increased risk of cardiovascular mortality and morbidity. It poses a major burden on global economy and healthcare systems. Particularly, the burden of diabetes is high in
developing countries because of rapid economic transformation, aging, urbanization, and lifestyle changes over a relatively short period and consequently, a more rapid increase in the prevalence of diabetes (4). Strong evidence indicates that T2DM can be prevented or delayed by modification of lifestyles (1, 5), which means that the burden of T2DM might be greatly reduced by prevention of diabetes in individuals at high-risk and early diagnosis or identification of undiagnosed patients with T2DM. During the last decades, advances in metabolomics have helped find many pathways or novel biomarkers involved in diabetes and its complications (6).

Metabolic disorders of carbohydrate, fat and protein follow diabetes after its diagnosis. These metabolic disturbances may occur well before onset or diagnosis of diabetes. Studies showed that abnormal protein metabolism was associated with insulin resistance (7) and oxidative stress (8). In patients with T2DM, the disturbance of protein metabolism is in a net catabolic state due to increased loss of nitrogen or negative nitrogen balance (i.e., amino acid catabolism is exaggerated and uptake of amino acids by tissues is reduced), even without protein restriction. Recently, studies reported that elevated levels of blood urea nitrogen were associated with increased risk of incident T2DM both in epidemiological studies (9) and experimental studies (10). Urea formation mainly occurs in the urea cycle in the liver, and the products and substrates of urinary metabolites include arginine, citrulline and ornithine. Animal data demonstrated significant differences of urinary metabolic profiles between high-fat-fed rats and their control rats (11, 12). Moreover, alterations of amino acids metabolism in urea cycle might be associated with insulin resistance (12). In the cycle, several enzymes involved in removal of nitrogen from amino acids are regulated by glucagon and insulin. These enzymes are also involved in synthesis of nitric oxide. In this regard, it is known that insulin has impacts on the activity of arginase (key enzyme in urea cycle) and nitric oxide synthase (NOS) (13, 14). Pietzner et al. (15) and Carracedo et al. (16) showed that amino acids involved in urea cycle were associated with inflammatory markers and oxidative stress. Given the connections between urea cycle disorder and many features of diabetes, we hypothesized that plasma levels of arginine, citrulline and ornithine were associated with the risk of T2DM.

Using a cross-sectional survey of 2,554 subjects in Jinzhou, China, we aimed to test the hypothesis that plasma levels of amino acids involved in the urea cycle were associated with the risk of T2DM.

**MATERIALS AND METHODS**

**Study Population and Settings**

Liaoning Medical University First Affiliated Hospital (LMUFAH) is a comprehensive tertiary care hospital serving a population of 3.1 million in Jinzhou city, Liaoning province, China. The subjects of this study included in-patients with newly diagnosed T2DM (duration of diabetes ≤ 2 years) and healthy subjects who took part in a routine health check-up in LMUFAH. The details of the study subjects were described elsewhere (17). Briefly, the subjects who were selected into the study underwent the measurement of metabolism profile on a voluntary basis at LMUFAH between May 2015 and August 2016. The exclusion criteria were: (1) below 18 years old; (2) being a local resident in the hospital’s catchment area for less than 6 months living prior to the study; (3) diabetes secondary to other diseases; and (4) mental diseases may bring trouble to complete health checks. The inclusion criteria included: (1) if being case group, patients with T2DM (duration ≤ 2 years) should be diagnosed by the 1999 World Health Organization’s criteria (18) or treated with antidiabetic medicines; and (2) if being control group, they did not have T2DM or other related diseases.

Based on the inclusion and exclusion criteria, we retrieved medical notes stored in a computer system to organize this hospital-based cross-sectional study. The retrieved data comprised anthropometric measurements, clinical laboratory assays, metabolism profile and other related data. Anthropometric data on height, weight and blood pressure were recorded. Clinical laboratory assays included glycated hemoglobin (HbA1c) (only available for patients with T2DM) and lipid profiles. Metabolomics assessment extracted data of amino acids involved in urea cycle, i.e., arginine, ornithine and citrulline. Additionally, drug use and diabetes complications, duration of diabetes were collected from all the subjects with T2DM. In total, we included data of 1,923 subjects (569 women and 1,354 men) in the analysis. Of them, 401 subjects had T2DM.

The protocol of the study was approved by the Ethics Committee for Clinical Research of LMUFAH and the informed consent was waived due to the nature of the retrospective study, which was in accordance with the Helsinki Declaration of 1964 and its later amendments.

**Data Collection and Definitions**

Body weight, height and blood pressure were measured by specially trained doctors and nurses using standardized methods. When measuring weight and height, participants were required to take off shoes and heavy clothing. The measurements of weight and height were rounded to the nearest 0.1 kg and 0.5 cm, respectively. Body mass index (BMI) was calculated by dividing weight in kilograms by squared height in meters. According to the criteria recommended by the National Health Commission in China (19), BMI was divided into four categories: underweight (<18.5 kg/m²), normal weight (18.5–23.9 kg/m²), obesity (24–27.9 kg/m²) and overweight (≥28 kg/m²). Blood pressure was measured after at least 10 min of rest in a sitting position.

Blood samples were collected from participants after an overnight fast of at least 8h. Lipid profile was assayed, including high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG). Low HDL-C was defined as less than 1 mmol/L in men and 1.3 mmol/L in women (20). The metabolomic profiling including arginine, ornithine and citrulline was measured in all subjects. Additionally, drug use and diabetes complications, duration of diabetes were collected from all the subjects with T2DM.

**Amino Acids Quantification**

The metabolomics assessment method has been described previously in detail (21). Briefly, the metabolomics approach was based on mass spectrometry (MS) technology. We collected
capillary whole blood after at least 8 h fasting which was stored as dried blood spot (DBS) and used in the assay of metabolomics. Metabolites in DBS were measured by direct infusion MS technology equipped with AB Sciex 4000 QTrap system (AB Sciex, Framingham, MA, USA). High-purity water and Acetonitrile from Thermo Fisher (Waltham, MA, USA) were used as diluting agent and mobile phase.1-Butanol and acetyl chloride from Sigma-Aldrich (St Louis, MO, USA) was used to derive samples. Isotope-labeled internal standard samples of 12 amino acids (NSK-A) were purchased from Cambridge Isotope Laboratories (Tewksbury, MA, USA) while standard samples of the amino acids were purchased from Chrom systems (Grafelfing, Germany).

Data Analyses and Statistics
Statistical analyses were performed using Statistical Analysis System (Release 9.2) (SAS Institute Inc., Cary, USA). Data were expressed as mean ± SD (standard deviation) if normal distributions were not rejected or expressed as median with interquartile (IQR). Categorical data were expressed as numbers (percentages). Student's t-test or Mann Whitney U test was used in continuous data and Chi-squared test was used in categorical data to compare the differences between two groups. Binary logistic regression was conducted to obtain odds ratios (ORs) and their 95% confidence intervals (CIs) of arginine, ornithine, citrulline and the ratios of any two of them for the risk of T2DM in univariate and multivariate analyses. Confounding factors including age, gender, BMI, systolic blood pressure, HDL-C, LDL-C and triglyceride were adjusted in multivariable models.

Sensitivity analysis was also performed to check consistency of the results after exclusion of patients with any diabetic complications. A p-value in all results less than 0.05 was accepted as statistically significant.

RESULTS
Characteristics of the Study Population
In this study, the mean age was 47.6 (SD: 14.1) years. Newly diagnosed patients with diabetes (duration ≤2 years) had the means of glycosylated hemoglobin (HbA1c) was 10.1% (SD: 2.4). About 12~14% of them had coronary heart disease and stroke, and 5~13% had diabetic retinopathy and diabetic nephropathy. Compared with control group, patients with T2DM were likely to be much older, lighter, shorter, and had lower concentrations of HDL-C and LDL-C, higher blood pressure and higher levels of triglyceride, but similar levels of BMI (Table 1).

For the metabolite profiles of amino acids in urea cycle, we observed significant differences in arginine and ornithine between the two groups. Compared with the control group, the serum concentrations of arginine was significantly higher and ornithine was markedly lower in patients with T2DM. Citrulline was similar between the two groups. In addition, the ratios of arginine to ornithine, arginine to citrulline and citrulline to ornithine were significantly higher in T2DM than in the control group (Table 1).

Associations Between Amino Acids and T2DM
Arginine was positively associated with the risk of T2DM in univariate analyses. After further adjustment for each amino acid, the positive association was still significant and were strengthened for arginine (OR: 1.26, 95% CI:1.21–1.30) (Table 2). However, ornithine was inversely associated with the risk of T2DM. The multivariable-adjusted OR of ornithine for T2DM were 0.90 (95% CI 0.88–0.91). After adjustment for traditional risk factors, the effect sizes of amino acids remained almost unchanged (OR for arginine: 1.28, 1.21–1.35 and OR for ornithine: 0.91, 0.90–0.93, respectively). Citrulline was associated with the risks of T2DM (1.03, 1.01–1.06) after adjusting for arginine and ornithine. But further adjustment for confounders, the association was non-significant (Table 2).

Ratios of Amino Acids and the Risk of T2DM
We further analyzed the associations between ratios of amino acids in the urea cycle and T2DM. The ratios of arginine to ornithine, arginine to citrulline and citrulline to ornithine were all significantly associated with T2DM. After adjustment for other ratios of amino acids, the multivariable ORs per 0.1 of arginine to ornithine, arginine to citrulline, as well as citrulline to ornithine for T2DM among participants were 1.44 (95% CI 1.08–1.92), 1.29 (95% CI 1.08–1.55) and 1.71 (95% CI 1.52–1.92), respectively. Further adjustment for traditional risk factors did not lead to large changes and the associations remained significant except the association between ratio of arginine to citrulline and T2DM (Table 2).

Sensitivity Analysis
After exclusion of patients with diabetic complications (n = 147), the effect sizes of arginine and ornithine, and their ratios for T2DM remained stable and significant in univariable and multivariable analyses (Table 3).

DISCUSSION
In this cross-sectional study, we found that the elevated levels of arginine but reduced levels of ornithine were associated with the increased odds of T2DM in Chinese. The ratios of arginine to ornithine and citrulline to ornithine were also associated with markedly increased risk of T2DM, associations being largely independent of traditional risk factors. Citrulline and the ratio of arginine to citrulline were not associated with T2DM.

As of disturbances of protein metabolism, patients with diabetes have a much higher rate of protein depletion but a lower rate of protein synthesis. In amino acid catabolism, most of the ammonia released is in the form of urea from a process of urea cycle of liver. It remains largely unknown whether amino acids in the urea cycle have any relationship with T2DM, especially in Chinese. Earlier experiment studies in mice (10, 22) showed that urea was associated with impaired beta cell function, elevated levels of reactive oxygen species production, reduced insulin sensitivity and glucose intolerance. Using a huge cohort
TABLE 1 | Clinical and biochemical characteristics of subjects according to occurrence of type 2 diabetes mellitus (T2DM).

| Variables                  | Non T2DM (1522) Mean/number (SD or %) | T2DM (401) Mean/number (SD or %) | P-value |
|----------------------------|---------------------------------------|-----------------------------------|---------|
| Age                        | 46.3 ± 13.7                           | 52.5 ± 14.5                       | <0.001  |
| Duration of diabetes, years|                                      |                                   |         |
| Male Gender                | 1131 (74.3%)                          | 223 (55.6%)                       | <0.001  |
| Weight, kg                 | 73.6 ± 13.5                           | 71.2 ± 14.3                       | 0.001   |
| Height, cm                 | 169.7 ± 8.0                           | 167.0 ± 8.1                       | <0.001  |
| BMI, kg/m²                 | 25.4 ± 3.5                            | 25.4 ± 4.2                        | 0.987   |
| BMI < 18.5                 | 23 (1.5%)                             | 14 (3.5%)                         |         |
| BMI ≥ 18.5 and < 24        | 504 (33.1%)                           | 132 (32.9%)                       |         |
| BMI ≥ 24 and < 28          | 653 (42.9%)                           | 156 (38.9%)                       |         |
| BMI ≥ 28                   | 342 (22.5%)                           | 99 (24.7%)                        |         |
| SBP, mmHg                  | 130.9 ± 17.2                          | 136.2 ± 22.3                      | <0.001  |
| DBP, mmHg                  | 81.0 ± 11.6                           | 83.1 ± 12.6                       | 0.002   |
| HDL-C, mmol/L              | 1.55 ± 0.35                           | 1.06 ± 0.35                       | <0.001  |
| LDL-C, mmol/L              | 3.06 ± 0.70                           | 2.93 ± 1.00                       | 0.007   |
| Triglyceride, mmol/L       | 4.47 (3.07–6.70)                      | 9.74 (5.33–16.61)                 | <0.001  |
| Arg, µmol/L                | 53.07 (36.41)                         | 17.01 (12.91–22.54)               | <0.001  |
| Orn, µmol/L                | 19.07 (14.99–24.06)                   | 18.5 (14.6–24.2)                  | 0.284   |
| Arg: Orn, %                | 7.76 (4.87–12.0)                      | 59.41 (31.80–93.99)               | <0.001  |
| Cit: Orn, %                | 24.01 (16.92–33.61)                   | 55.29 (29.94–84.51)               | <0.001  |
| Cit: Orn, %                | 32.00 (23.11–44.71)                   | 110.69 (79.87–143.54)             | <0.001  |
| HbA1C, %                   | 10.1 ± 2.4                            |                                   |         |

MACROVASCULAR COMPLICATIONS

- Prior CHD: 48 (12.0%)
- Prior stroke: 57 (14.2%)

MICROVASCULAR COMPLICATIONS

- Diabetic retinopathy: 22 (5.5%)
- Diabetic nephropathy: 53 (13.2%)

DRUG USE

- Oral antidiabetic drugs: 235 (58.6%)
- Insulin: 287 (71.6%)
- Statins: 141 (35.2%)
- Other lipid lowering drugs: 11 (2.7%)
- ACEIs: 34 (8.5%)
- ARBs: 39 (9.7%)
- Other antihypertensive drugs: 80 (20.0%)

BMI, body mass index; SBP/DBP, systolic/diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; Arg, arginine; Orn, ornithine; Cit, citrulline; HbA1C, glycated hemoglobin; CHD, coronary heart disease; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists. Data are mean (SD), median (IQR), or n (%); P-values were derived from Chi-square test or Student t-test.

of 1,337,452 subjects in USA, Xie et al. (9) found that elevated levels of blood urea nitrogen augmented the risk of T2DM.

In this connection, our study observed that increased levels of arginine but decreased level of ornithine, as well as their related ratios were associated with newly diagnosed T2DM. These observations suggested that abnormal urea cycle metabolism in the liver might derange as compared with the normal people. Our findings are supported by a study conducted in USA (23) showing that the level of arginine was higher in patients with diabetes than in control subjects, although some studies showed that the level of arginine was reduced in patients with T2DM (12, 24, 25). Given the close link between T2DM and urea, we speculate that elevated levels of arginine may increase urea synthesis, because arginine can activate N-acetylglutamate synthase (AGA) which further activates carbamoyl phosphate synthetase-I (CPS-I) to start urea cycle. On the other hand, arginine is involved in nitric oxide (NO) synthesis in citrulline-NO cycle (26). Enhancement of NOS activity could augment blood flow to insulin-sensitive tissues.
### Table 2 | Odds ratio of amino acids and ratios of amino acids for the risk of type 2 diabetes mellitus.

| Beta OR  | 95%CI    | P-value | AUC  |
|----------|----------|---------|------|
| **UNIVARIABLE MODEL 1** | | | |
| Arginine, µmol/L | 0.18 | 1.20 | 1.17–1.23 | <0.0001 | 0.759 |
| Ornithine, µmol/L | −0.11 | 0.89 | 0.88–0.91 | <0.0001 | 0.936 |
| Citrulline, µmol/L | −0.002 | 1.00 | 0.98–1.01 | 0.790 | 0.517 |
| Multivariable Model 1 | | | |
| Arginine, µmol/L | 0.23 | 1.26 | 1.21–1.30 | <0.0001 | 0.954 |
| Ornithine, µmol/L | −0.11 | 0.89 | 0.88–0.91 | <0.0001 | 0.936 |
| Citrulline, µmol/L | 0.03 | 1.03 | 1.01–1.06 | 0.0199 | 0.517 |
| Multivariable Model 2* | | | |
| Arginine, µmol/L | 0.25 | 1.28 | 1.21–1.35 | <0.0001 | 0.969 |
| Ornithine, µmol/L | −0.09 | 0.91 | 0.90–0.93 | <0.0001 | 0.936 |
| Citrulline, µmol/L | 0.02 | 1.02 | 0.98–1.06 | 0.3889 | 0.517 |
| **UNIVARIABLE MODEL 2** | | | |
| Arginine:Ornithine, per 0.1 | 1.15 | 3.16 | 2.79–3.58 | <0.0001 | 0.944 |
| Arginine:Citrulline, per 0.1 | 0.49 | 1.64 | 1.55–1.74 | <0.0001 | 0.789 |
| Citrulline:Ornithine, per 0.1 | 0.67 | 1.96 | 1.83–2.09 | <0.0001 | 0.939 |
| Multivariable Model 3 | | | |
| Arginine:Ornithine, per 0.1 | 0.36 | 1.44 | 1.06–1.92 | 0.0141 | 0.960 |
| Arginine:Citrulline, per 0.1 | 0.25 | 1.29 | 1.08–1.55 | 0.0060 | 0.939 |
| Citrulline:Ornithine, per 0.1 | 0.54 | 1.71 | 1.52–1.92 | <0.0001 | 0.939 |
| Multivariable Model 4* | | | |
| Arginine:Ornithine, per 0.1 | 0.58 | 1.78 | 1.20–2.65 | 0.0044 | 0.982 |
| Arginine:Citrulline, per 0.1 | 0.16 | 1.17 | 0.91–1.51 | 0.2165 | 0.982 |
| Citrulline:Ornithine, per 0.1 | 0.47 | 1.59 | 1.37–1.86 | <0.0001 | 0.982 |

OR, odds ratio; CI, confidence interval; AUC, area under the curve.

*Adjusted for age, gender, body mass index, systolic blood pressure, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride.

NO is an endogenous AMPK activator and can indirectly represses lipogenesis or gluconeogenesis (27). Probably, our results suggest that there is a lower conversion of arginine to citrulline in diabetic patients and that NOS activity associated with arginine metabolism is impaired, leading to reduce NO bioactivity. The arguments are consistently with the previous studies (28). Tessari et al. (28) analyzed the trial of 8 patients with T2DM and 10 control subjects, and reported that NO synthesis was reduced due to a defective arginine conversion to NOx rather than substrate-limited.

Plasma ornithine concentration was markedly lower in patients with T2DM than the controls. In this regard, another previous study found that plasma levels of ornithine were inversely associated with inflammation marker (15). It can be inferred that lower levels of ornithine might be a feature of inflammatory conditions. Meanwhile, the decreased levels of ornithine might stem from increased depletion of ornithine. Experimental research demonstrated that expression of ornithine decarboxylase was up-regulated in very early stage of diabetes (29). Increased activity of ornithine decarboxylase might promote conversion of ornithine to putrescine. Nevertheless, it is still unknown that the over-degradation of ornithine to putrescine are due to diabetes itself or to insulin resistance.

Our study had several limitations worth noting. First, the major limitation of this study is cross-sectional design, no causal relationship between disorder of urea cycle metabolism and diabetes can be derived. It is noticed that protein metabolism disorder is one of the typical symptoms of T2DM. Therefore, it is possible that the changes of arginine, citrulline and ornithine are the results from diabetes and complications. In our sensitivity analysis, the effects of amino acids on T2DM were relatively stable and suggested that, at least in part, these associations were more likely a cause rather than a consequence of complication (i.e., diabetic nephropathy). Second, our subjects with T2DM were in-patients with T2DM and they may have more severe T2DM than those non-hospitalized patients with T2DM. Although we only included those patients with onset of T2DM within 2 years and made careful adjustment for disease severity such as onset age, blood pressure, lipid profile and diabetes complication, the plasma glucose effects and confounding effect of disease severity may not be completely removed. Further studies are needed to validate these findings in well-designed surveys or cohorts. Third, it is a pity that many important variables such as lifestyle factors and concentration of urea were not documented or measured, which limited us to further analyze alterations related with amino acids in urea cycle.

Our study has important implications for public health. The diabetes epidemic poses a major health and economy threat to the world including China. Nowadays, China has over 113.9 million adults with T2DM, and the extreme increase in the prevalence of...
diabetes and its complications are expected in the future. Strong evidence indicates that many cases of T2DM could be prevented by lifestyle interventions. Thus, it is critically important to develop an accurate model to identify individuals at high risk of developing T2DM in order to prevent its development in the future. However, a number of predictive models failed to accurately predict incident T2DM (30), even including genetic factors used in the predicting tools (31). Our study suggests that amino acids in urea cycle may be candidate markers for predicting T2DM in Chinese if these findings can be replicated in cohort studies, especially in China.

In conclusion, our findings suggested that amino acids involved in urea cycling were associated with T2DM. Further cohort studies are warranted to replicate our findings to check whether the plasma levels of amino acids involved in urea cycle have predictive values for T2DM in the future.

**AUTHOR CONTRIBUTIONS**

XY and Z-ZF conceived and designed the study. JLi and Y-FC analyzed the data and wrote the first draft. ZZ participated in further revision after receiving the reviewers’ comments. JLiu, X-FF, H-HL, WY and S-NL provided data collection. X-YS gave critical comments and contributed to the writing of this manuscript. All authors approved the final version of this manuscript. XY, Z-ZF, Y-FC, JLi and ZZ take full responsibility for the study as a whole, including the study design, access to data, and the decision to submit and publish the manuscript.

**FUNDING**

This work was supported by the project for the National Key Research and Development Program (2016YFC0903100, 2016YFC0903102), the thirteenth 5 years plan and TMU talent project (11601501/2016KJ0313), National Natural Science Foundation of China (No. 81602826, 81672961), individualized diagnosis and treatment of colorectal cancer (No. LNCCC-B05-2015), Foundation of Committee on Science and Technology of Tianjin (Grant No. 15JCYBJC54700), the China Postdoctoral Science Foundation (2016M590210), Tianjin Health Bureau Science Foundation Key Project (16KG154), and Tianjin Project of Thousand Youth Talents.

**ACKNOWLEDGMENTS**

The authors thank all doctors, nurses and research staff at the Liaoning Medical University (FAHLMU) in Jinzhou, for their participation in this study.
REFERENCES

1. International Diabetes Federation. *IDF Diabetes Atlas*-7th Edition 2015. Available online at: https://www.idf.org/ (Accessed December 1, 2015).

2. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neil B. The global burden of diabetes and its complications: an emerging pandemic. *Eur J Cardiovasc Prev Rehabil.* (2010) 17(Suppl. 1):S3–8. doi: 10.1097/H.JR.0b013e3181f1.s4d15a

3. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA (2013) 310:948–59. doi: 10.1001/jama.2013.168118

4. Chan JC, Malik V, Jia W, Kadowaki T, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. *JAMA* (2009) 301:2129–40. doi: 10.1001/jama.2009.726

5. American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. *Diabetes Care* (2018) 41(Suppl. 1):S13–27. doi: 10.2337/dc18-S002

6. Bain JR. Targeted metabolomics finds its mark in diabetes research. *Diabetes* (2013) 62:349–51. doi: 10.2337/db12-1189

7. Tessari P, Cecchet D, Cosma A, Puricelli L, Millioni R, Vedovato M, et al. Insulin resistance of amino acid and protein metabolism in type 2 diabetes. *Clin Nutr.* (2011) 30:267–72. doi: 10.1016/j.clnu.2011.02.009

8. Raino JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. *Free Radic Biol Med.* (2011) 50:567–75. doi: 10.1016/j.freeradbiomed.2010.12.006

9. Xie Y, Rowe B, Li T, Xian H, Yan Y, Al-Aly Z. Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. *Kidney Int.* (2018) 93:741–52. doi: 10.1016/j.kint.2017.08.033

10. Koppe L, Nyam E, Vivot K, Manning Fox JE, Dai XQ, Nguyen BN, et al. Urea impairs beta cell glycolysis and insulin secretion in chronic kidney disease. *J Clin Invest.* (2016) 126:3598–612. doi: 10.1172/JCI86181

11. Kim SH, Yang SO, Kim HS, Kim Y, Park T, Choi HK. 1H-nuclear magnetic resonance spectroscopy-based metabolic assessment in a rat model of obesity induced by a high-fat diet. *Anal Bioanal Chem.* (2009) 395:1117–24. doi: 10.1007/s00216-009-3054-8

12. Li LO, Hu YF, Wang L, Mitchell M, Berger A, Coleman RA. Early hepatic insulin resistance in mice: a metabolomics analysis. *Mol Endocrinol.* (2010) 24:657–66. doi: 10.1209/mc.2009-0152

13. Kashyap SR, Roman LJ, Lamont J, Masters BS, Bajaj M, Suraamornkul S, et al. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. *J Clin Endocrinol Metab.* (2005) 90:1100–5. doi: 10.1210/jc.2004-0745

14. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. *Circ Res.* (2008) 102:95–102. doi: 10.1161/CIRCRESAHA.107.155028

15. Pietzner M, Kaul A, Henning AK, Henning AK, Kastenmüller G, Artati A, Lerch MM, et al. Comprehensive metabolic profiling of chronic low-grade inflammation among generally healthy individuals. *BMJ Clin Med.* (2017) 15:210. doi: 10.1186/s12391-017-0974-6

16. Caraccao J, Merino A, Briceno C, Soriano S, Buendia P, Calleros L, et al. Carbamyalted low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells. *FASEB J.* (2011) 25:1314–22. doi: 10.1096/fj.10-173377

17. Li J, Cao YF, Sun XY, Han L, Li SN, Gu WQ, et al. Plasma tyrosine and its interaction with low-high density lipoprotein cholesterol and the risk of type 2 diabetes mellitus in Chinese. *J Diabetes Invest.* (2018). doi: 10.1111/jdi.12898. [Epub ahead of print].

18. Alberti KG, Zimet PD. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med.* (1998) 15:539–53. doi: 10.1002/(SICI)1096-9166(199807)15:7<539::AID-DIA668>3.0.CO;2-S

19. National Health Commission of the People’s Republic of China. *Criteria of Weight for Adults* (2013). Available online at: http://www.moh.gov.cn/ewebeditor/uploadfile/2013/08/20130801435715967.pdf (Accessed June 22, 2017).

20. Wang Q, Sun T, Cao Y, Gao P, Dong J, Yang Y, et al. A dried blood spot mass spectrometry metabolic approach for rapid breast cancer detection. *Onco Targets Ther.* (2016) 9:1389–98. doi: 10.2147/OTT.S95862

21. D’Apolito M, Du X, Zong H, Catucci A, Maiuri L, Trivisano T, et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. *J Clin Invest.* (2010) 120:203–13. doi: 10.1172/JCI37672

22. Malecki MT, Undas A, Cyganek K, Mirkiewicz-Sieradzka B, Wolkow P, Osmenda G, et al. Plasma asymmetric dimethylarginine (ADMA) is related to retinopathy in type 2 diabetes. *Diab Care* (2007) 30:2899–901. doi: 10.2337/dc07-1138

23. Ganz T, Wainstein J, Gilad S, Limor R, Boaz M, Stern N. Serum asymmetric dimethylarginine and arginine levels predict microvascular and macrovascular complications in type 2 diabetes mellitus. *Diab Metab Res Rev.* (2017) 33:e2836. doi: 10.1002/dmrr.2836

24. Menge BA, Schrader H, Ritter PR, Ellrichmann M, Uhl W, Schmidt WE, et al. Selective amino acid deficiency in patients with impaired glucose tolerance and type 2 diabetes. *Regul Pept.* (2010) 160:75–80. doi: 10.1016/j.regpep.2009.08.001

25. Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. *Annu Rev Nutr.* (2002) 22:87–105. doi: 10.1146/annurev.nutr.22.110801.140547

26. Zhang J, Xie Z, Dong Y, Wang S, Liu C, Zou MH. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. *J Biol Chem.* (2008) 283:27452–61. doi: 10.1074/jbc.M802578200

27. Tessari P, Cecchet D, Cosma A, Vettore M, Coracina A, Millioni R, et al. Nitric oxide synthesis is reduced in subjects with type 2 diabetes and nephropathy. *Diabetes* (2010) 59:2152–9. doi: 10.2337/db09-1772

28. Deng A, Munger KA, Valdivielso JM, Satriano J, Lortie M, Blantz RC, et al. Increased expression of ornithine decarboxylase in distal tubules of early diabetic rat kidneys: are polyamines paracrine hypertrophic factors? *Diabetes* (2003) 52:1235–9. doi: 10.2337/diabetes.52.5.1235

29. Collins GS, Mallett S, Omar O, Yu LM. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. *BMJ Med.* (2011) 9:103. doi: 10.1136/bmj.s1705.9-103

30. Lyssenko V, Laakso M. Genetic screening for the risk of type 2 diabetes: worthless or valuable? *Diab Care* (2013) 36(Suppl. 2):S120–6. doi: 10.2337/dc13-S009

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Cao, Li, Zhang, Liu, Sun, Peng, Luo, Yang, Li, Yang and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.